- FDA approves Plan B One-Step OTC switch
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
- FDA approves liquid form of enalapril to treat BP in children, adults
- Former CMS, FDA chief McClellan delivers keynote at Cardinal Health RBC
SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by GlaxoSmithKline and Xenoport for treating restless legs syndrome, the agency said Thursday.
The FDA approved Horizant (gabapentin enacarbil) as a once-daily treatment for moderate-to-severe RLS.
“People with restless legs syndrome can experience considerable distress from their symptoms,” FDA Division of Neurology Products director Russell Katz said. “Horizant provides significant help in treating these symptoms.”